Drugs / Sulodexide

Trials 13 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT00583427 Dec 2007 → Dec 2009 dense deposit disease University of Iowa Withdrawn No outcome recorded
Phase 35 trials
Phase 3 NCT06982196 Apr 2025 → Jun 2026 overdue psoriasis Xijing Hospital Enrolling by invitation No outcome recorded
Phase 3 NCT05005052 Nov 2021 → Dec 2023 chronic venous insufficiency Value Outcomes Ltd. Unknown No outcome recorded
Phase 3 NCT03370705 Jan → Dec 2019 peripheral arterial occlusive disease 1 Alfa Wassermann Tunisia Unknown No outcome recorded
Phase 3 NCT00462202 Apr 2007 → Mar 2008 diabetic kidney disease Keryx Biopharmaceuticals Terminated No outcome recorded
Phase 3 NCT00130208 Aug 2005 → Jan 2008 diabetic kidney disease Keryx Biopharmaceuticals Completed No outcome recorded
Phase 45 trials
Phase 4 NCT05252923 Apr → Sep 2022 COVID-19, thrombotic disease Pirogov Russian National Research Medical University Terminated No outcome recorded
Phase 4 NCT03504566 Nov 2017 → Jun 2019 diabetic kidney disease Steno Diabetes Center Copenhagen Withdrawn No outcome recorded
Phase 4 NCT02512601 Sep 2015 → Feb 2017 post-thrombotic syndrome Bama GeVe, S.L.U. Terminated No outcome recorded
Phase 4 NCT01316068 Mar 2011 → Aug 2012 diabetic kidney disease, proteinuria Sun Yat-sen University Unknown No outcome recorded
Phase 4 NCT00130312 Aug 2005 → Mar 2008 diabetic kidney disease Keryx Biopharmaceuticals Terminated No outcome recorded
Phase not applicable2 trials
NCT05654233 Feb → Aug 2023 chronic venous insufficiency, peripheral vascular disease, varicose disease Chengdu University of Traditional Chinese Medicine Unknown No outcome recorded
NCT04180137 Nov 2019 → Dec 2020 chronic venous insufficiency State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia Completed No outcome recorded
Also used as a comparator or background therapy in 6 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 22 trials
Phase 2 NCT02737670 Comparator Aug 2014 → Mar 2017 tinnitus St Joseph University, Beirut, Lebanon Completed No outcome recorded
Phase 2 NCT01295775 Comparator Feb 2009 → Apr 2011 background diabetic retinopathy Ajou University School of Medicine Completed No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT04483830 Comparator Jun → Aug 2020 COVID-19 Clinedem Completed No outcome recorded
Phase 33 trials
Phase 3 NCT05371925 Comparator Jun 2023 → Feb 2024 post-COVID-19 disorder, thrombotic disease Centro Medico del Noroeste Completed No outcome recorded
Phase 3 NCT04257487 Comparator Dec 2020 → Dec 2025 overdue venous thromboembolism Arianna Anticoagulazione Foundation Recruiting No outcome recorded
Phase 3 NCT01000545 Comparator Nov 2009 → Jan 2011 chronic kidney disease Corbridge Group Philippines, Inc. Unknown No outcome recorded

Evidence & citations 10 cited values

Every value below carries the sentence it was read from. 21 sources stand behind the page.

FieldValueCited text
Known as Sulodexide “This study compares the efficacy and safety of sulodexide (Vessel) to placebo in patients with chronic venous disease of the lower extremities.” NCT05005052
18

“After surgical intervention the active treatment group will receive sulodexide 250 lipasemic units (LSU) bid for 30 days.” NCT04180137

NCT00130208

NCT05654233

NCT00583427

NCT03504566

NCT03370705

NCT04483830

NCT05252923

NCT00130312

NCT02737670

NCT01316068

NCT01000545

NCT06982196

NCT01295775

NCT02512601

NCT05371925

NCT04257487

NCT00462202

Known as KRX-101 “An Open Label Tolerability and Safety Study of KRX-101 (Sulodexide Gelcaps) for the Treatment of Type 2 Diabetic Nephropathic Patients With Persistent Microalbuminuria in...” NCT00462202
Known as KRX-101 (sulodexide) KRX-101 (sulodexide)NCT00583427
Known as SLX SLXNCT01000545
Known as Sulodexida ChEMBL registry synonym — accepted as the source's own label CHEMBL2108086
Known as Vessel “This study compares the efficacy and safety of sulodexide (Vessel) to placebo in patients with chronic venous disease of the lower extremities.” NCT05005052
Known as Vessel due f ChEMBL registry synonym — accepted as the source's own label CHEMBL2108086
Known as Vessel due F (Alfasgima SpA, Italy) Vessel due F (Alfasgima SpA, Italy)NCT05371925
Modality Other / unclassified “Sulodexide, a heterogenous group of sulfated glycosaminoglycans” PMID 21872376 Aug 2011
Route Oral “administered orally twice a day.” NCT00130208